PET Scanning Improves Treatment of Esophageal Cancer, University of Pittsburgh Study Finds

OncologyONCOLOGY Vol 10 No 12
Volume 10
Issue 12

Using positron emission tomography (PET) scanning may improve the treatment of patients with cancer of the esophagus, potentially resulting in lower morbidity, according to surgeons at the University of Pittsburgh Medical Center.

Using positron emission tomography (PET) scanning may improvethe treatment of patients with cancer of the esophagus, potentiallyresulting in lower morbidity, according to surgeons at the Universityof Pittsburgh Medical Center.

James Luketich, md, assistant professor of surgery in the divisionof cardiothoracic surgery, codirector of the University of PittsburghCancer Institute's Lung Cancer Center, and director of the thoraciconcology program, is the principal investigator of this preliminarystudy of the role of PET scanning in the treatment of esophagealcancer. The study's findings were presented on October 26, 1996,at the meeting of the Institute for Clinical PET in Orlando, Florida.

"The purpose of this study is to investigate the effectivenessof PET in determining whether or not a patient's esophageal cancerhas spread to other parts of the body. Such knowledge is importantin determining the type of treatment the patient receives,"Dr. Luketich said. "For instance, if we find that cancerhas spread to the lymph nodes and to other tissue, surgery mightnot be a good option. However, if it is found that cancer hasnot spread, then perhaps surgery and chemotherapy would be thebest approach."

"We studied 21 patients and the PET scan showed 10 tumorsnot previously seen by X-rays or CT scans that had spread to thelymph nodes and seven other tumors that had spread to other areasof the body," Dr. Luketich said. "Overall, the effectivenessof PET in detecting cancer that has spread was 80%."

"Although this study included only a limited number of patients,PET scanning has already proven to be a valuable tool in the treatmentof esophageal cancer patients," Dr. Luketich said.

Related Videos
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Farshid Dayyani, MD, PhD
Related Content